Date: 2012-04-26
Type of information:
phase:
Announcement: results
Company: Teva Pharmaceutical Industries (Israel)
Product: Copaxone® (glatiramer acetate injection)
Action mechanism:
Disease: relapsing-remitting multiple sclerosis (RRMS)
Therapeutic area: Autoimmune diseases - Neurodegenerative diseases
Country:
Trial details: The prospective longitudinal survey research study is evaluating 110 participants utilizing the Multiple Sclerosis Spasticity Scale (MSSS-88), the Performance Scales, and a socio demographic questionnaire completed when transitioning between treatments and at month six. Study criteria included participants who had stopped interferon-beta treatment within 30 days; were about to start, or started Copaxone® within the previous 21 days; had spasticity; and were able to ambulate with unilateral support or without. Of the 52 participants, whose data are currently being reported, 35 percent were taking medication for spasticity prior to enrollment and during the six month period.
Latest
news: Teva Pharmaceutical Industries has announced interim data from a prospective, open label survey study evaluating spasticity in patients with relapsing-remitting multiple sclerosis (RRMS) who transitioned to Copaxone® (glatiramer acetate injection) from interferon-beta treatment. These data were presented at the 64th Annual Meeting of the American Academy of Neurology (AAN) in New Orleans, Louisiana.
Interim results for the first 52 of 110 participants revealed a significant reduction in muscle stiffness, pain and discomfort, as well as the effect of spasticity on the ability to walk, body movements and activities of daily living (ADLs). Improvement was also found in reduction of total spasticity scores during the six month period.
